Filing Flows › Vivos Therapeutics (VVOS) › Q3 2025
Vivos Therapeutics (VVOS) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 19, 2025
Vivos Therapeutics (VVOS) reported revenue of $6.8M for the third quarter 2025 (Q3 2025), +76% from a year earlier and +78% from the quarter before. Operating margin was -69.8%, net loss $5.4M (79.6% of revenue).
Vivos Therapeutics, Q3 2025: revenue $6.8M (+76% year over year), operating margin -69.8%, net loss $5.4M, operating cash flow −$4.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.8M | +78% | +76% |
| Operating profit | −$4.7M | — | — |
| Net earnings | −$5.4M | — | — |
| Operating cash flow | −$4.2M | — | — |
What changed
Revenue was $6.8M in Q3 2025, up 76% year over year and up 78% from the previous quarter. Sleep Testing Services was the largest line at 38% of revenue. Sleep Testing Services added $2.2M year over year (up 678%), 76% of the total change. VIP declined 91%.
Gross margin was 58.0%, down 2.4 points from a year earlier. Operating costs exceeded revenue by $4.7M, an operating margin of -69.8%. Operating expenses grew 74% against revenue growth of 76%. The fastest-growing cost line was Other operating costs (+163%). The quarter ended with a net loss of $5.4M, wider than the previous quarter's $5.0M loss.
Operating cash flow was −$4.2M. Non-cash charges added back $384K of depreciation and amortization and $55K of share-based compensation. Working capital and other items added $800K. Capital expenditures of −$83K exceeded it, leaving free cash flow of −$4.1M.
Questions
What was Vivos Therapeutics' revenue in the third quarter 2025?
Vivos Therapeutics (VVOS) reported revenue of $6.8M for the third quarter 2025 (Q3 2025), +76% from a year earlier and +78% from the quarter before.
Was Vivos Therapeutics profitable in the third quarter 2025?
Operating loss was $4.7M (-69.8% of revenue) and net loss $5.4M.
Source: Vivos Therapeutics 10-Q on SEC EDGAR.